Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geordi Pang

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Frontiers in Oncology|September 14, 2016
Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective TrialsHarvey C Quon, Hima Bindu Musunuru, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2005
Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancerPatrick Cheung, Katharina Sixel, Gerard Morton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 8, 2013
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomesAndrew Loblaw, Patrick Cheung, Laura D'Alimonte, et al.
Practical Radiation Oncology|May 20, 2019
5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate BedKevin Martell, Patrick Cheung, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2011
Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancerHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|January 18, 2011
Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicityHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 29, 2018
Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trialsYasir Alayed, Patrick Cheung, Geordi Pang, et al.
International Journal of Radiation Oncology, Biology, Physics|March 22, 2008
Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity resultsTee S Lim, Patrick C F Cheung, D Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|September 14, 2016
Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective TrialsHarvey C Quon, Hima Bindu Musunuru, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2005
Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancerPatrick Cheung, Katharina Sixel, Gerard Morton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 8, 2013
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomesAndrew Loblaw, Patrick Cheung, Laura D'Alimonte, et al.
Practical Radiation Oncology|May 20, 2019
5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate BedKevin Martell, Patrick Cheung, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2011
Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancerHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|January 18, 2011
Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicityHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 29, 2018
Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trialsYasir Alayed, Patrick Cheung, Geordi Pang, et al.
International Journal of Radiation Oncology, Biology, Physics|March 22, 2008
Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity resultsTee S Lim, Patrick C F Cheung, D Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Pageof 3